Monophasic, Cohesive-polydensified-matrixCrosslinking-technology-based Hyaluronic AcidFiller for the Treatment of Facial Lipoatrophyin HIV-infected Patients

June 2010 | Volume 9 | Issue 6 | Case Reports | 690 | Copyright © June 2010

Tatjana Pavicic MD, Thomas Ruzicka MD, Hans-Christian Korting MD, Gerd Gauglitz MD MMS

Human immunodeficiency virus (HIV)-associated facial lipoatrophy (FLA) represents a common and highly stigmatizing side effect of retroviral therapy. By causing loss of subcutaneous adipose tissue mainly in the cheek, temple and periocular area, FLA can significantly affect the patient’s quality of life, both physically and psychologically. A limited quantity of data has been published on various filling substances for the management of FLA. Here, the authors present two patients with HIV-associated FLA successfully treated with a novel HA filler over a period of 24 months.